– Milestone payments include $5.25 million cash and $2.25 million purchase of Precision stock – – Cash received supports Precision’s expected cash runway through 2028 and strategic focus on in vivo gene editing pipeline – DURHAM, N.C. --(BUSINESS WIRE)--Mar. 2, 2026-- Precision BioSciences, Inc.